With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.Iovance Biotherapeutics (IOVA 7.54%) is going to finish the week strong on the stock market if its Thursday performance is any indication. Investors boosted the company's share price by almost 8%, following the initiation of coverage by an analyst who's bullish on its future. With that rise, Iovance easily eclipsed the S&P 500 index's 0.2% increase.Vast potential with melanoma drugThe analyst launching his Iovance ...